Mycosis fungoides medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 6: | Line 6: | ||
==Medical Therapy== | ==Medical Therapy== | ||
* Patients with Mycosis fungoides are treated based on the stage and the previous treatment history.<ref name="pmid24421750">{{cite journal |vauthors=Al Hothali GI |title=Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach |journal=Int J Health Sci (Qassim) |volume=7 |issue=2 |pages=220–39 |date=June 2013 |pmid=24421750 |pmc=3883611 |doi= |url=}}</ref> | * Patients with Mycosis fungoides are treated based on the stage and the previous treatment history.<ref name="pmid24421750">{{cite journal |vauthors=Al Hothali GI |title=Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach |journal=Int J Health Sci (Qassim) |volume=7 |issue=2 |pages=220–39 |date=June 2013 |pmid=24421750 |pmc=3883611 |doi= |url=}}</ref> | ||
* Treatment is weitten as early disease (stage IA, IB, IIA) and advanced disease) | * Treatment is weitten as early disease (stage IA, IB, IIA) and advanced disease)<ref name="WillemzeHodak2018">{{cite journal|last1=Willemze|first1=R|last2=Hodak|first2=E|last3=Zinzani|first3=P L|last4=Specht|first4=L|last5=Ladetto|first5=M|title=Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†|journal=Annals of Oncology|volume=29|issue=Supplement_4|year=2018|pages=iv30–iv40|issn=0923-7534|doi=10.1093/annonc/mdy133}}</ref> | ||
===Mycosis fungoides (Early stages)=== | ===Mycosis fungoides (Early stages)=== | ||
Revision as of 19:36, 14 December 2018
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.[1]
Medical Therapy
- Patients with Mycosis fungoides are treated based on the stage and the previous treatment history.[2]
- Treatment is weitten as early disease (stage IA, IB, IIA) and advanced disease)[3]
Mycosis fungoides (Early stages)
- Stage IA
- Patients with mycosis fungoides in stage IA ( patches, plaques, may be papules involve <10 % of total skin surface) treat by skin-directed therapy [topical corticosteroids, nitrogen mustard (meclorethamin, NH2)].
- Skin direct therapy is recommended more than systemic therapy (chemotherapy+ skin direct therapy) in this stage.[2]
- Systemic therapies +/- topical therapy are recommended for patients who intolerant of topical treatments
- Stage IB-IIA
- Generalized skin directed therapy with or without combination other skin directed therapies[4]
- In majority of patients in this stages, skin directed therapy (topical corticosteroid, HN2, ultraviolet B (UVB) therap) recommended use more than systemic therapy.
- Generalized skin directed therapy with or without combination other skin directed therapies[4]
- The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.[1]
Stage | PUVA | Topical chemotherapy | Systemic chemotherapy | Radiotherapy | Biological therapy | Retinoid therapy | Photopheresis |
---|---|---|---|---|---|---|---|
Stage I |
|
|
|
|
|
|
--------- |
Stage II |
|
|
|
|
|
|
--------- |
Stage III |
|
|
|
|
|
|
|
Stage IV |
|
|
|
|
|
|
|
Recurrent cutaneous T cell lymphoma |
|
|
|
|
|
--------- | --------- |
Treatment | Description | |
---|---|---|
Phototherapy or Ultraviolet light therapy | ||
PUVA (psoralen and ultraviolet A light therapy) |
| |
Ultraviolet B (UVB) light |
| |
Chemotherapy | ||
Topical chemotherapy |
| |
Systemic chemotherapy |
| |
Radiation therapy | ||
Local external beam radiation therapy |
| |
Total skin electron beam (TSEB) therapy |
| |
Biological therapy | ||
Interferon alfa |
| |
Denileukin diftitox |
| |
Retinoid therapy | ||
Retinoids |
| |
Photopheresis | ||
Photopheresis |
|
- During treatment with systemic retinoids, lipid panel and thyroid function tests should be closely monitored
- Gemfibrozil should be avoided because of the known side effects of the combined therapy; fish oil tablets can be used instead
- Some authors have also documented liver toxicities associated with administration of retinodis, and liver function tests (LFTs) should also be monitored in these patients.
- ↑ 1.0 1.1 1.2 1.3 Cutaneous T cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/cutaneous-t-cell-lymphoma/?region=on Accessed on January 19, 2016
- ↑ 2.0 2.1 Al Hothali GI (June 2013). "Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach". Int J Health Sci (Qassim). 7 (2): 220–39. PMC 3883611. PMID 24421750.
- ↑ Willemze, R; Hodak, E; Zinzani, P L; Specht, L; Ladetto, M (2018). "Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†". Annals of Oncology. 29 (Supplement_4): iv30–iv40. doi:10.1093/annonc/mdy133. ISSN 0923-7534.
- ↑ Kim YH, Chow S, Varghese A, Hoppe RT (January 1999). "Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides". Arch Dermatol. 135 (1): 26–32. PMID 9923777.